Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.48 |
| ▸ | TACR1 | P25103 | 2/20 | 0.43 |
| ▸ | CCR8 | P51685 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3687281 | 0.85 | CCR8 (0.45) | KCNH2CCR8ROCK2MTNR1AMTNR1B | |
| SCHEMBL13145572 | 0.81 | KCNH2 (0.65) | KCNH2TACR1CCR8 | |
| SCHEMBL3684975 | 0.80 | TACR1 (0.44) | KCNH2TACR1ROCK2MTNR1AMTNR1B | |
| SCHEMBL3691654 | 0.79 | KCNH2 (0.60) | KCNH2 | |
| SCHEMBL3692134 | 0.78 | KCNH2 (0.61) | KCNH2TACR1CCR8 | |
| SCHEMBL6216150 | 0.73 | CCR8 (0.46) | KCNH2CCR8MTNR1AMTNR1B | |
| SCHEMBL3688184 | 0.72 | ROCK2 (0.54) | KCNH2ROCK2MTNR1AMTNR1B | |
| SCHEMBL30915540 | 0.69 | CYP2D6 (0.61) | KCNH2ROCK2 | |
| SCHEMBL30915544 | 0.69 | CYP2D6 (0.61) | KCNH2ROCK2 | |
| SCHEMBL3687109 | 0.68 | KCNH2 (0.73) | KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2239260-A1 | Novel compounds with antibacterial activity | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2010-10-13 | — | — | EP | disclosed |
| US-7223776-B2 | Compounds with anti-bacterial activity | MORPHOCHEM AG (DE) | 2007-05-29 | — | — | US | disclosed |
| US-20060040949-A1 | Novel compounds with antibacterial activity | MORPHOCHEM AG | 2006-02-23 | — | — | US | disclosed |
| EP-1551829-A2 | NOVEL COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) | 2005-07-13 | — | — | EP | disclosed |
| WO-2004035569-A2 | NOVEL COMPOUNDS WITH ANTIBACTERIAL ACTIVITY | Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) | 2004-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040949-A1 | Novel compounds with antibacterial activity | MRPL21, Q6ZSR9, MRPL19 | KCNH2 2411/4885TACR1 3827/4885CCR8 3798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.